Dual NK1/NK3 antagonists against schizophrenia

Details for Australian Patent Application No. 2005268895 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Schnider, Patrick

Agent Spruson & Ferguson

Pub. Number AU-B-2005268895

PCT Pub. Number WO2006/013050

Priority 04103794.6 06.08.04 EP

Filing date 27 July 2005

Wipo publication date 9 February 2006

Acceptance publication date 17 March 2011

International Classifications

C07D 213/82 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/4436 (2006.01)

A61K 31/4439 (2006.01)

A61K 31/444 (2006.01)

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

Event Publications

15 March 2007 PCT application entered the National Phase

  PCT publication WO2006/013050 Priority application(s): WO2006/013050

17 March 2011 Application Accepted

  Published as AU-B-2005268895

21 July 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under reg. 22.2I(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005268899-Substituted N-acyl-2-aminothiazoles

2005268894-Benzyloxy derivatives as MAOB inhibitors